210,000 Shares in Benitec Biopharma Inc. (NASDAQ:BNTC) Acquired by Infinitum Asset Management LLC

Infinitum Asset Management LLC bought a new position in shares of Benitec Biopharma Inc. (NASDAQ:BNTC - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 210,000 shares of the biotechnology company's stock, valued at approximately $2,652,000. Benitec Biopharma accounts for 1.4% of Infinitum Asset Management LLC's portfolio, making the stock its 14th largest holding. Infinitum Asset Management LLC owned 0.90% of Benitec Biopharma at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Franklin Resources Inc. increased its stake in shares of Benitec Biopharma by 269.0% in the fourth quarter. Franklin Resources Inc. now owns 2,939,287 shares of the biotechnology company's stock worth $37,123,000 after purchasing an additional 2,142,643 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Benitec Biopharma by 134.7% in the 4th quarter. Geode Capital Management LLC now owns 197,096 shares of the biotechnology company's stock worth $2,490,000 after buying an additional 113,109 shares during the period. MYDA Advisors LLC purchased a new stake in Benitec Biopharma in the 4th quarter worth $632,000. Adage Capital Partners GP L.L.C. raised its holdings in Benitec Biopharma by 134.4% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 1,972,524 shares of the biotechnology company's stock valued at $24,913,000 after acquiring an additional 1,131,129 shares during the period. Finally, Northern Trust Corp lifted its position in shares of Benitec Biopharma by 54.2% in the fourth quarter. Northern Trust Corp now owns 38,200 shares of the biotechnology company's stock valued at $482,000 after acquiring an additional 13,425 shares in the last quarter. Hedge funds and other institutional investors own 52.19% of the company's stock.

Insider Buying and Selling

In other Benitec Biopharma news, Director Suvretta Capital Management, L bought 900,000 shares of the company's stock in a transaction on Wednesday, March 26th. The stock was acquired at an average price of $13.00 per share, for a total transaction of $11,700,000.00. Following the completion of the transaction, the director now directly owns 8,793,245 shares of the company's stock, valued at approximately $114,312,185. This represents a 11.40% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 1.30% of the stock is owned by corporate insiders.

Benitec Biopharma Price Performance

Shares of Benitec Biopharma stock traded up $1.82 during trading hours on Wednesday, reaching $16.14. The company's stock had a trading volume of 69,145 shares, compared to its average volume of 41,337. The firm has a 50 day moving average price of $13.44 and a 200-day moving average price of $12.20. The stock has a market cap of $413.18 million, a P/E ratio of -10.69 and a beta of 0.34. Benitec Biopharma Inc. has a one year low of $5.74 and a one year high of $16.90.

Benitec Biopharma (NASDAQ:BNTC - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.12. As a group, sell-side analysts forecast that Benitec Biopharma Inc. will post -1.48 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on BNTC. JMP Securities reiterated a "market outperform" rating and issued a $20.00 price target on shares of Benitec Biopharma in a report on Thursday, May 15th. HC Wainwright restated a "buy" rating and set a $28.00 price objective on shares of Benitec Biopharma in a research report on Monday, May 19th. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $24.71.

About Benitec Biopharma

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.